7/4/2025

Janusmed sex and gender

Janusmed sex and gender – Baricitinib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Baricitinib

Baricitinib

Class : A

Show all info

Print

Contact us

  1. Olumiant (baricitinib). EPAR - Product information. European Medicines Agency [updated 2025-01-16, cited 2025-06-03]

  2. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.

  3. Johansson EK, Bergström A, Kull I, Melén E, Jonsson M, Lundin S et al. Prevalence and characteristics of atopic dermatitis among young adult females and males-report from the Swedish population-based study BAMSE. J Eur Acad Dermatol Venereol. 2022;36(5):698-704.

  4. Thompson AR, Tziotzios C, Nesnas J, Randall R, Czachorowski M, Messenger AG. Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study. Br J Dermatol. 2024;191(6):924-935.

  5. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112-7.

  6. Food and Drug Administration (FDA). Medical Review - Olumiant (baricitinib). Drugs@FDA [www]. [updated 2018-05-31, cited 2025-06-03].

  7. Martinez-Molina C, Feliu A, Park HS, Juanes A, Diaz-Torne C, Vidal S et al. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. J Clin Med. 2024;13(8):.

  8. Baldi C, Berlengiero V, Falsetti P, Cartocci A, Conticini E, D'Alessandro R et al. Baricitinib retention rate: 'real-life' data from a mono-centric cohort of patients affected by rheumatoid arthritis. Front Med (Lausanne). 2023;10:1176613.

  9. Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022;12(1):134.

  10. Wada-Irimada M, Takahashi T, Sekine M, Okazaki T, Takahashi T, Chiba T et al. Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center. J Dermatol. 2025;52(4):701-711.

  11. Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555-570.

  12. Martinez-Molina C, Gich I, Diaz-Torné C, Park HS, Feliu A, Vidal S et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14(1):172.

  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Olumiant (baricitinib). EPAR - Product information. European Medicines Agency [updated 2025-01-16, cited 2025-06-03]
  2. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9.
  3. Johansson EK, Bergström A, Kull I, Melén E, Jonsson M, Lundin S et al. Prevalence and characteristics of atopic dermatitis among young adult females and males-report from the Swedish population-based study BAMSE. J Eur Acad Dermatol Venereol. 2022;36(5):698-704.
  4. Thompson AR, Tziotzios C, Nesnas J, Randall R, Czachorowski M, Messenger AG. Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study. Br J Dermatol. 2024;191(6):924-935.
  5. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112-7.
  6. Food and Drug Administration (FDA). Medical Review - Olumiant (baricitinib). Drugs@FDA [www]. [updated 2018-05-31, cited 2025-06-03].
  7. Martinez-Molina C, Feliu A, Park HS, Juanes A, Diaz-Torne C, Vidal S et al. Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. J Clin Med. 2024;13(8):.
  8. Baldi C, Berlengiero V, Falsetti P, Cartocci A, Conticini E, D'Alessandro R et al. Baricitinib retention rate: 'real-life' data from a mono-centric cohort of patients affected by rheumatoid arthritis. Front Med (Lausanne). 2023;10:1176613.
  9. Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022;12(1):134.
  10. Wada-Irimada M, Takahashi T, Sekine M, Okazaki T, Takahashi T, Chiba T et al. Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center. J Dermatol. 2025;52(4):701-711.
  11. Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555-570.
  12. Martinez-Molina C, Gich I, Diaz-Torné C, Park HS, Feliu A, Vidal S et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Sci Rep. 2024;14(1):172.
  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]